Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;59(3):1789-93.
doi: 10.1128/AAC.04191-14. Epub 2014 Dec 22.

In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations

Henry Li  1 , Mark Estabrook  1 , George A Jacoby  2 , Wright W Nichols  3 , Raymond T Testa  3 , Karen Bush  4
Affiliations

In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations

Henry Li et al. Antimicrob Agents Chemother. 2015 Mar.

Abstract

Avibactam, a broad-spectrum β-lactamase inhibitor, was tested with ceftazidime, ceftaroline, or aztreonam against 57 well-characterized Gram-negative strains producing β-lactamases from all molecular classes. Most strains were nonsusceptible to the β-lactams alone. Against AmpC-, extended-spectrum β-lactamase (ESBL)-, and KPC-producing Enterobacteriaceae or Pseudomonas aeruginosa, avibactam lowered ceftazidime, ceftaroline, or aztreonam MICs up to 2,048-fold, to ≤4 μg/ml. Aztreonam-avibactam MICs against a VIM-1 metallo-β-lactamase-producing Enterobacter cloacae and a VIM-1/KPC-3-producing Escherichia coli isolate were 0.12 and 8 μg/ml, respectively.

PubMed Disclaimer

References

    1. Ehmann DE, Jahić H, Ross PL, Gu R-F, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup KG, Fisher SL. 2013. Kinetics of avibactam inhibition against class A, C, and D β-lactamases. J Biol Chem 288:27960–27971. doi:10.1074/jbc.M113.485979. - DOI - PMC - PubMed
    1. Sader HS, Flamm RK, Jones RN. 2013. Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. medical centers in 2010-2011. Antimicrob Agents Chemother 57:1982–1988. doi:10.1128/AAC.02436-12. - DOI - PMC - PubMed
    1. Aktaş Z, Kayacan C, Oncul O. 2012. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 39:86–89. doi:10.1016/j.ijantimicag.2011.09.012. - DOI - PubMed
    1. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390–394. doi:10.1128/AAC.00756-10. - DOI - PMC - PubMed
    1. Bush K. 2013. Carbapenemases: partners in crime. J Global Antimicrob Resist 1:7–16. doi:10.1016/j.jgar.2013.01.005. - DOI - PubMed

Publication types

MeSH terms